TherapeuticsMD (TXMD) Other Non-Current Liabilities (2012 - 2026)
TherapeuticsMD (TXMD) posted Other Non-Current Liabilities of $873000.0 for Q1 2026, little changed on a QoQ basis from $873000.0 in Q4 2025, and up 9.81% year-over-year from $795000.0 in Q1 2025.
TherapeuticsMD (TXMD) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
TherapeuticsMD's Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $873000.0 for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 9.81% year-over-year to $873000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $873000.0 (up 9.81% YoY) and the FY2025 annual result came in at $873000.0, up 17.34% from the prior year.
- Other Non-Current Liabilities was $873000.0 for Q1 2026 at TherapeuticsMD, roughly flat from $873000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.2 million in Q1 2022 and bottomed at $554000.0 in Q2 2022.
- A 5-year average of $854764.7 and a median of $832000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 48.25% — and 2023, when it jumped 114.62%.
- TherapeuticsMD's Other Non-Current Liabilities stood at $1.1 million in 2022, then slumped by 42.55% to $636000.0 in 2023, then gained by 16.98% to $744000.0 in 2024, then rose by 17.34% to $873000.0 in 2025, then changed by 0.0% to $873000.0 in 2026.
- Business Quant data shows TXMD's Other Non-Current Liabilities at $873000.0 in Q1 2026, $873000.0 in Q4 2025, and $871000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 873,000.00 |
| Dec 31, 2025 | 873,000.00 |
| Sep 30, 2025 | 871,000.00 |
| Jun 30, 2025 | 832,000.00 |
| Mar 31, 2025 | 795,000.00 |
| Dec 31, 2024 | 744,000.00 |
| Sep 30, 2024 | 705,000.00 |
| Jun 30, 2024 | 637,000.00 |
| Mar 31, 2024 | 637,000.00 |
| Dec 31, 2023 | 636,000.00 |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 1.11 Mn |
| Sep 30, 2022 | 554,000.00 |
| Jun 30, 2022 | 554,000.00 |
| Mar 31, 2022 | 1.23 Mn |
| Dec 31, 2021 | 2.14 Mn |
| Sep 30, 2021 | 758,000.00 |
| Jun 30, 2021 | 358,000.00 |